Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Jabbour, Elias J  [Clear All Filters]
2019
Chamoun, K., Milton, D.R., Ledesma, C., Young, K.H., Jabbour, E.J., Alatrash, G., Anderlini, P., Bashir, Q., Ciurea, S.O., Marin, D., et al. (2019). Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results.Biol Blood Marrow Transplant.
Ravandi, F., Assi, R., Daver, N., Benton, C.B., Kadia, T., Thompson, P.A., Borthakur, G., Alvarado, Y., Jabbour, E.J., Konopleva, M., et al. (2019). Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.Lancet Haematol.
Corbacioglu, S., Jabbour, E.J., and Mohty, M. (2019). Risk Factors for Development of and Progression of Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.Biol Blood Marrow Transplant.
Sasaki, K., Kantarjian, H.M., Kadia, T., Patel, K., Loghavi, S., Garcia-Manero, G., Jabbour, E.J., DiNardo, C., Pemmaraju, N., Daver, N., et al. (2019). Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.Cancer.
Jabbour, E.J., Gökbuget, N., Kantarjian, H.M., Thomas, X., Larson, R.A., Yoon, S.-S., Ghobadi, A., Topp, M.S., Tran, Q., Franklin, J.L., et al. (2019). Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.Cancer.